TuHURA Biosciences, Inc. HURA 深 沪
等待开盘 06-25 09:30:00 美东时间
2.52
-0.120
-4.55%
华盛通- 最 高2.70
- 今 开2.58
- 成交量 42.85万股
- 最 低 2.45
- 昨 收 2.64
- 总市值 1.60亿
- 52周最高 3.90
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 0.41
- 委 比 -89.08%
- 总股本 6368.25万
- 历史最高 190225.00
- 量 比 0.61
- 振 幅 9.47%
- 历史最低 0.41
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administrati...
06-15 19:52
TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share
05-16 05:27
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses
The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC. Under the terms of the loan agreement, TuHURA will have the ability to draw down monthly on the facility on an as-needed basis
04-22 19:37
美股牛股 | 半导体概念股ALMU大涨超42%！获美政府超400万美元合同，加速半导体量子通信平台发展；RVMD狂飙超41%
半导体概念股ALMU大涨超42%！获美政府合同，加速半导体量子通信平台发展；RVMD狂飙超41%，胰腺癌靶向药III期试验成功，患者生存期接近翻倍>>
04-14 19:23
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 56.4% to $0.16 du...
04-14 01:05
TuHURA Biosciences Files $50M At-The-Market Common Stock Offering With H.C. Wainwright As Sales Agent
$50,000,000Common StockWe have entered into an At the Market Offering Agreement (the "Sales Agreement"), dated November 3, 2025, with H.C. Wainwright & Co., LLC (the "Sales Agent"), relating to the shares
04-09 04:35
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or th...
04-07 19:45
TuHURA Biosciences Q4 EPS $(0.13) Beats $(0.14) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 3.7 percent. This is a 90.51 percent increase over losses of $(1.37) per share from
04-01 19:52
TuHURA Biosciences Regains Nasdaq Compliance
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26,
02-27 20:30
